Thomas McCourt Net Worth

The estimated Net Worth of Thomas A Mccourt is at least 19.2 百万$ dollars as of 20 May 2024. Mr. Mccourt owns over 67,618 units of Ironwood Pharmaceuticals Inc stock worth over 5,003,936$ and over the last 15 years he sold IRWD stock worth over 9,048,227$. In addition, he makes 5,104,330$ as President at Ironwood Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McCourt IRWD stock SEC Form 4 insiders trading

Thomas has made over 35 trades of the Ironwood Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 67,618 units of IRWD stock worth 436,136$ on 20 May 2024.

The largest trade he's ever made was exercising 220,000 units of Ironwood Pharmaceuticals Inc stock on 30 August 2019 worth over 1,073,600$. On average, Thomas trades about 21,165 units every 58 days since 2010. As of 20 May 2024 he still owns at least 1,150,330 units of Ironwood Pharmaceuticals Inc stock.

You can see the complete history of Mr. Mccourt stock trades at the bottom of the page.

Thomas McCourt biography

Thomas A. McCourt serves as President of the Company. He has served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of Zelnorm for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec® and NEXIUM®. Mr. McCourt serves on the board of directors of Acceleron Pharma Inc. and has a degree in pharmacy from the University of Wisconsin.

What is the salary of Thomas McCourt?

As the President of Ironwood Pharmaceuticals Inc, the total compensation of Thomas McCourt at Ironwood Pharmaceuticals Inc is 5,104,330$. There are 1 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of 10,068,800$.

How old is Thomas McCourt?

Thomas McCourt is 62, he's been the President of Ironwood Pharmaceuticals Inc since 2019. There are 4 older and 14 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.

What's Thomas McCourt's mailing address?

Thomas's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Ironwood Pharmaceuticals Inc

Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over 83,928,361$ worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth 24,100,589$ . The most active insiders traders include Llc Fmr、Bryan E Roberts、Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of 239,611$. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth 42,316$.

What does Ironwood Pharmaceuticals Inc do?

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Complete history of Mr. Mccourt stock trades at Acceleron Pharma Inc、Ironwood Pharmaceuticals Inc、Pliant Therapeutics

Ironwood Pharmaceuticals Inc executives and stock owners

Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Mallon,
  Chief Executive Officer, Director
• Thomas McCourt,
  President
• Mark Currie,
  Director
• Gina Consylman,
  Chief Financial Officer, Senior Vice President
• Thomas A. McCourt,
  CEO & Director
• Jason Rickard,
  COO & Sr. VP of Operations
• Dr. Michael Shetzline M.D., Ph.D.,
  Chief Medical Officer, Sr. VP and Head of R&D
• Catherine Moukheibir,
  Independent Director
• Jon Duane,
  Independent Director
• Marla Kessler,
  Independent Director
• Julie McHugh,
  Independent Chairman of the Board
• Andrew Dreyfus,
  Independent Director
• Edward Owens,
  Independent Director
• Lawrence Olanoff,
  Independent Director
• Julie H. McHugh,
  Exec. Chairman
• Alexander Denner,
  Director
• Meredith Kaya,
  Vice President - Investor Relations and Corporate Communications
• Michael Shetzline,
  Chief Medical Officer, Senior Vice President and Head of Drug Development
• Conor Kilroy,
  Senior Vice President, General Counsel
• Jason Rickard,
  Chief Operating Officer, Senior Vice President
• John Minardo,
  Sr. VP & Chief Legal Officer
• Marcel Moulaison,
  VP of Technical Operations
• Ronald Silver,
  Corp. Controller & Principal Accounting Officer
• Sravan Kumar Emany,
  Sr. VP & CFO
• G. Todd Milne,
  Co-Founder and VP of sGC R&D
• Brian M. Cali,
  Co-Founder and Sr. VP of R&D Strategy & External Innovation
• Terrance Mcguire,
  Director
• Douglas E Williams,
  Director
• Amy W Schulman,
  Director
• Marsha Fanucci,
  Director
• Christopher T Phd Walsh,
  Director
• Peter M Hecht,
  Chief Executive Officer
• Thomas Graney,
  Chief Financial Officer
• William Huyett,
  Chief Operating Officer
• Halley E Gilbert,
  Chief Admin Officer & SVP
• Bryan E Roberts,
  Director
• Associatesvenrock Associate...,
  
• Management Llc Vr,
  10% owner
• Llc Fmr,
  10% owner
• Llcfil Ltd Fmr,
  
• Co Investment Holdings, Llc...,
  
• Capital Investments L.P.Rid...,
  
• Joseph C Jr Cook,
  Director
• George H Conrades,
  Director
• David Evans Shaw,
  Director
• David A Ebersman,
  Director
• Michael J Higgins,
  Chief Operating Officer
• Kelly Mac Donald,
  Chief Accounting Officer
• Jay Shepard,
  
• Sravan Kumar Emany,
  SVP, Chief Financial Officer
• Alexander J Sarissa Capital...,
  
• Andrew Davis,
  SVP, Chief Business Officer
• Ronald Silver,
  Principal Accounting Officer
• Minardo John,
  Chief Legal Officer